Cargando…
Molecular Vaccines From Prophylaxis to Therapy - Volume 2 /
This title discusses all aspects of non-infectious and non-cancer- so called NINC - vaccines. Hypertension, diabetes and allergy vaccine development are referred to as well as the use of adjuvants and nanotechnology in vaccine development. The way of novel vaccines from bench to preclinical to clini...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Cham :
Springer International Publishing : Imprint: Springer,
2014.
|
| Edición: | 1st ed. 2014. |
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-319-00978-0 | ||
| 003 | DE-He213 | ||
| 005 | 20220117045441.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 131107s2014 sz | s |||| 0|eng d | ||
| 020 | |a 9783319009780 |9 978-3-319-00978-0 | ||
| 024 | 7 | |a 10.1007/978-3-319-00978-0 |2 doi | |
| 050 | 4 | |a RM300-666 | |
| 072 | 7 | |a MMG |2 bicssc | |
| 072 | 7 | |a MED044000 |2 bisacsh | |
| 072 | 7 | |a MKG |2 thema | |
| 082 | 0 | 4 | |a 615 |2 23 |
| 245 | 1 | 0 | |a Molecular Vaccines |h [electronic resource] : |b From Prophylaxis to Therapy - Volume 2 / |c edited by Matthias Giese. |
| 250 | |a 1st ed. 2014. | ||
| 264 | 1 | |a Cham : |b Springer International Publishing : |b Imprint: Springer, |c 2014. | |
| 300 | |a XXVIII, 870 p. 98 illus., 74 illus. in color. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a Non-infectious and non-cancer vaccines -- Adjuvants and nanotechnology -- In silico and delivery systems -- Patenting, manufacturing, registration. | |
| 520 | |a This title discusses all aspects of non-infectious and non-cancer- so called NINC - vaccines. Hypertension, diabetes and allergy vaccine development are referred to as well as the use of adjuvants and nanotechnology in vaccine development. The way of novel vaccines from bench to preclinical to clinical studies and launch to the market under EMEA (European Medicines Agency) and FDA (Food and Drug Administration) guidelines are described in-depth. Practical perspectives of patentability of vaccines are discussed. The book is therefore of interest for researchers and clinicians engaged in vaccine development and molecular vaccine application. | ||
| 650 | 0 | |a Pharmacology. | |
| 650 | 0 | |a Immunology. | |
| 650 | 0 | |a Medicine-Research. | |
| 650 | 0 | |a Biology-Research. | |
| 650 | 1 | 4 | |a Pharmacology. |
| 650 | 2 | 4 | |a Immunology. |
| 650 | 2 | 4 | |a Biomedical Research. |
| 700 | 1 | |a Giese, Matthias. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783319009797 |
| 776 | 0 | 8 | |i Printed edition: |z 9783319009773 |
| 776 | 0 | 8 | |i Printed edition: |z 9783319376752 |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-3-319-00978-0 |z Texto Completo |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||